Status:
COMPLETED
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
Lead Sponsor:
Facet Biotech
Conditions:
Crohn's Disease
Colitis
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of the HARMONY study is to assess the safety and efficacy of an investigational drug called HuZAF, in patients with moderate to severe Crohn's disease (CD). HuZAF is a humanized anti-Inter...
Detailed Description
Participants will be randomized, assigned by chance, to one of five treatment groups consisting of: four groups differing in the amount of study drug given and one placebo group. The initial dose of s...
Eligibility Criteria
Inclusion
- Patients 18-70 years old
- Patients with moderate to severe Crohn's disease
- Patients who have had Crohn's disease for at least 6 months
- Patients who have previously been treated for Crohn's disease
Exclusion
Key Trial Info
Start Date :
March 1 2002
Trial Type :
INTERVENTIONAL
End Date :
April 1 2004
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT00072943
Start Date
March 1 2002
End Date
April 1 2004
Last Update
March 13 2012
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Advanced Clinical Research Institute
Anaheim, California, United States, 92801
2
Doctor's Office
Orange, California, United States, 92868
3
Gainesville VA Medical Center
Gainesville, Florida, United States, 32608
4
Waterside Clinical Research Services, Inc.
West Palm Beach, Florida, United States, 33407